Literature DB >> 22543272

Gene-specific patterns of coregulator requirements by estrogen receptor-α in breast cancer cells.

Kwang Won Jeong1, Rajas Chodankar, Daniel J Purcell, Danielle Bittencourt, Michael R Stallcup.   

Abstract

Progesterone receptor (PgR) controls the menstrual cycle, pregnancy, embryonic development, and homeostasis, and it plays important roles in breast cancer development and progression. However, the requirement of coregulators for estrogen-induced expression of the PgR gene has not been fully explored. Here we used RNA interference to demonstrate dramatic differences in requirements of 10 different coregulators for estrogen-regulated expression of six different genes, including PgR and the well-studied TFF1 (or pS2) gene in MCF-7 breast cancer cells. Full estrogen-induced expression of TFF1 required all ten coregulators, but PgR induction required only four of the 10 coregulators. Chromatin immunoprecipitation studies demonstrated several mechanisms responsible for the differential coregulator requirements. Actin-binding coregulator Flightless-I, required for TFF1 expression and recruited to that gene by estrogen receptor-α (ERα), is not required for PgR expression and not recruited to that gene. Protein acetyltransferase tat-interactive protein 60 and ATP-dependent chromatin remodeler Brahma Related Gene 1 are recruited to both genes but are required only for TFF1 expression. Histone methyltransferase G9a is recruited to both genes and required for estrogen-induced expression of TFF1 but negatively regulates estrogen-induced expression of PgR. In contrast, histone methyltransferase myeloid/lymphoid or mixed-lineage leukemia 1 (MLL1), pioneer factor Forkhead box A1, and p160 coregulator steroid receptor coactivator-3 are required for expression of and are recruited to both genes. Depletion of MLL1 decreased ERα binding to the PgR and TFF1 genes. In contrast, depletion of G9a enhanced ERα binding to the PgR gene but had no effect on ERα binding to the TFF1 gene. These studies suggest that differential promoter architecture is responsible for promoter-specific mechanisms of gene regulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543272      PMCID: PMC3355545          DOI: 10.1210/me.2012-1066

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  58 in total

1.  CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators.

Authors:  Jeong Hoon Kim; Hongwei Li; Michael R Stallcup
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

2.  Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains.

Authors:  Judd C Rice; Scott D Briggs; Beatrix Ueberheide; Cynthia M Barber; Jeffrey Shabanowitz; Donald F Hunt; Yoichi Shinkai; C David Allis
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

3.  Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes.

Authors:  Avtar Roopra; Romena Qazi; Barry Schoenike; Timothy J Daley; John F Morrison
Journal:  Mol Cell       Date:  2004-06-18       Impact factor: 17.970

4.  Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.

Authors:  C M Klinge; S C Jernigan; K A Mattingly; K E Risinger; J Zhang
Journal:  J Mol Endocrinol       Date:  2004-10       Impact factor: 5.098

5.  Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites.

Authors:  Larry N Petz; Yvonne S Ziegler; Jennifer R Schultz; Hwajin Kim; J Kim Kemper; Ann M Nardulli
Journal:  J Steroid Biochem Mol Biol       Date:  2004-02       Impact factor: 4.292

6.  Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter.

Authors:  Raphaël Métivier; Graziella Penot; Michael R Hübner; George Reid; Heike Brand; Martin Kos; Frank Gannon
Journal:  Cell       Date:  2003-12-12       Impact factor: 41.582

7.  Estrogen receptor alpha and activating protein-1 mediate estrogen responsiveness of the progesterone receptor gene in MCF-7 breast cancer cells.

Authors:  Larry N Petz; Yvonne S Ziegler; Margaret A Loven; Ann M Nardulli
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

8.  Transcription factor accessibility and histone acetylation of the progesterone receptor gene differs between parental MCF-7 cells and a subline that has lost progesterone receptor expression.

Authors:  Xiaojie Xu; Fern E Murdoch; Edward M Curran; Wade V Welshons; Michael K Fritsch
Journal:  Gene       Date:  2004-03-17       Impact factor: 3.688

9.  Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity.

Authors:  Young-Ho Lee; Hugh D Campbell; Michael R Stallcup
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

10.  PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing.

Authors:  Ildikó Gyory; Jian Wu; György Fejér; Edward Seto; Kenneth L Wright
Journal:  Nat Immunol       Date:  2004-02-22       Impact factor: 25.606

View more
  38 in total

1.  Estrogen receptor β (ERβ1) transactivation is differentially modulated by the transcriptional coregulator Tip60 in a cis-acting element-dependent manner.

Authors:  Ming-Tsung Lee; Yuet-Kin Leung; Irving Chung; Pheruza Tarapore; Shuk-Mei Ho
Journal:  J Biol Chem       Date:  2013-07-15       Impact factor: 5.157

2.  Expressomal approach for comprehensive analysis and visualization of ligand sensitivities of xenoestrogen responsive genes.

Authors:  Toshi Shioda; Noël F Rosenthal; Kathryn R Coser; Mizuki Suto; Mukta Phatak; Mario Medvedovic; Vincent J Carey; Kurt J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

3.  Changes in Gene Expression and Estrogen Receptor Cistrome in Mouse Liver Upon Acute E2 Treatment.

Authors:  Gaëlle Palierne; Aurélie Fabre; Romain Solinhac; Christine Le Péron; Stéphane Avner; Françoise Lenfant; Coralie Fontaine; Gilles Salbert; Gilles Flouriot; Jean-François Arnal; Raphaël Métivier
Journal:  Mol Endocrinol       Date:  2016-05-10

4.  Functions of nuclear actin-binding proteins in human cancer.

Authors:  Xinyi Yang; Ying Lin
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

5.  Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells.

Authors:  Ming Li Jin; Young Woong Kim; Hong Lan Jin; Hoin Kang; Eun Kyung Lee; Michael R Stallcup; Kwang Won Jeong
Journal:  Int J Cancer       Date:  2018-10-04       Impact factor: 7.396

Review 6.  Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling.

Authors:  Vineela Kadiyala; Catharine L Smith
Journal:  Mol Endocrinol       Date:  2014-03-19

7.  Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.

Authors:  Koen M A Dreijerink; Anna C Groner; Erica S M Vos; Alba Font-Tello; Lei Gu; David Chi; Jaime Reyes; Jennifer Cook; Elgene Lim; Charles Y Lin; Wouter de Laat; Prakash K Rao; Henry W Long; Myles Brown
Journal:  Cell Rep       Date:  2017-03-07       Impact factor: 9.423

8.  Selective coregulator function and restriction of steroid receptor chromatin occupancy by Hic-5.

Authors:  Rajas Chodankar; Dai-Ying Wu; Daniel S Gerke; Michael R Stallcup
Journal:  Mol Endocrinol       Date:  2015-03-12

9.  The genomic landscape of breast cancer as a therapeutic roadmap.

Authors:  Matthew J Ellis; Charles M Perou
Journal:  Cancer Discov       Date:  2013-01       Impact factor: 39.397

10.  Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.

Authors:  George Notas; Marilena Kampa; Vassiliki Pelekanou; Maria Troullinaki; Yves Jacquot; Guy Leclercq; Elias Castanas
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.